Blood Pressure and Ketamine Care: Understanding the Safety Conversation

A blood-pressure reading before ketamine treatment is not administrative paperwork. It is part of evaluating whether the treatment is appropriate that day and how the team will respond if pressure rises afterward. The useful patient question is not simply whether ketamine can raise blood pressure. It is whether the clinic has a clear, product-specific process that accounts for personal medical history, symptoms, and the ability to respond to complications.

Why the treatment team asks about vascular disease

The Spravato prescribing information, FDA, 2025 warns that esketamine can increase blood pressure and lists important contraindications, including aneurysmal vascular disease, arteriovenous malformation, and a history of intracerebral hemorrhage. These are not diagnoses patients are expected to rule out themselves. They are reasons to disclose known conditions, previous events, and specialist advice before a session. A clinician needs that information to decide whether additional assessment or a different treatment is appropriate.

Bring records if a medical history is complicated or terminology is unclear. Saying that a past scan showed a blood-vessel problem may be enough to prompt retrieval of the report. Do not assume that a problem is irrelevant because it occurred years ago or because another clinician considered it stable. Conversely, a single elevated home reading does not establish a diagnosis or independently determine eligibility for every ketamine-related intervention.

Baseline readings have context

Ask how the clinic measures baseline pressure and handles an unexpected result. Anxiety, recent exertion, pain, and measurement technique can affect a reading, but they should not be used to dismiss a concerning value automatically. The team may repeat the measurement and assess symptoms. The important point is that interpretation belongs to a qualified clinician using the product instructions and the person's overall risk, not to a patient trying to pass a screening test.

The esketamine label includes guidance for evaluating elevated baseline pressure and weighing a possible delay. Those instructions are not a universal threshold chart for all ketamine routes. IV treatment practices and patients' conditions differ. This article deliberately does not provide a number at which a reader should self-clear treatment. Ask the clinic to explain its own protocol and how that protocol relates to the evidence and regulatory framework for the product.

Share medicines and substances honestly

A medication list should include prescribed drugs, over-the-counter products, supplements, and recent substance use. The esketamine label calls for close blood-pressure monitoring with psychostimulants or monoamine oxidase inhibitors. That does not mean a reader should stop either treatment independently. The prescribing clinicians should discuss whether an interaction changes the plan and how any necessary adjustment would be made safely.

Tell the team if you missed a usual blood-pressure medicine or received instructions from another specialist. Do not take extra medication to obtain a lower reading before an appointment unless specifically directed. The goal is accurate assessment, not a favorable-looking measurement. Our medication-reconciliation article explains how to make conflicting instructions visible before they become a problem on treatment day.

Monitoring is more than one number

For esketamine, the dated FDA label describes assessment before dosing, reassessment around the period when blood concentrations peak, and further monitoring as clinically warranted. It also requires observation for other important effects. Passing a blood-pressure check does not eliminate the possibility of sedation, dissociation, or respiratory depression. A clinic should explain who observes the patient, what equipment is available, and how clinical concerns are escalated.

The FDA's warning about compounded ketamine identifies increased blood pressure among its safety concerns. An oral formulation or remote appointment does not make cardiovascular risk disappear. Ask who can assess a concerning reading or symptom if treatment occurs outside a clinic, and what the emergency plan is. Do not assume that a consumer cuff and a video connection offer the same safeguards as an appropriately staffed monitored setting.

Symptoms require a response, not an internet comparison

Chest pain, severe shortness of breath, a sudden severe headache, or neurological symptoms require urgent assessment. During a monitored visit, alert staff immediately. After leaving, seek emergency help for severe or sudden symptoms rather than waiting for an email reply. This is not a claim that these events are common; it is a reason to know the response plan before beginning care.

For a broader view of clinic readiness, see our ketamine safety and consent guide. A good consultation leaves the patient knowing which medical history matters, what monitoring will occur, and whom to contact afterward. Reassurance should come from a transparent process and individualized evaluation, not from statements that a low dose is automatically safe or that a prior uneventful session guarantees every future session will be uncomplicated.

Medical disclaimer: This article provides general education, not diagnosis, individualized treatment advice, or emergency care. Evidence and regulatory statements refer to the dated sources cited, not an exhaustive verification of all changes through October 30, 2026.

Sources

1. Spravato prescribing information, FDA, 2025
2. FDA warning about compounded ketamine, October 10, 2023